Clinical Trial Detail

NCT ID NCT02740920
Title Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

melanoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.